GFR-话题@MedSci

#GFR#

483篇内容 | 2533人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1534280, encodeId=655315342805b, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lung Cancer：吸烟影响EGFR基因突变发生来了和突变模式, objectType=article, longId=58359, objectId=61f458359f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61f458359f7, replyNumber=0, likeNumber=69, createdTime=2015-11-06, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61f458359f7, moduleTitle=Lung Cancer：吸烟影响EGFR基因突变发生来了和突变模式, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61f458359f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534279, encodeId=fa3c15342e97b, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lancet Oncol：吉非替尼联合铂类化疗用于一线采用吉非替尼治疗的EGFR突变NSCLC进展后治疗并不优于单纯化疗（IMPRESS研究）, objectType=article, longId=56654, objectId=5c1456654c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c1456654c5, replyNumber=0, likeNumber=71, createdTime=2015-09-29, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c1456654c5, moduleTitle=Lancet Oncol：吉非替尼联合铂类化疗用于一线采用吉非替尼治疗的EGFR突变NSCLC进展后治疗并不优于单纯化疗（IMPRESS研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c1456654c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534278, encodeId=e8a415342e833, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=吉非替尼联合培美曲塞一线治疗EGFR突变的东亚晚期NSCLC患者优于单纯吉非替尼（JMIT研究）, objectType=article, longId=56652, objectId=5e4b5665248, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e4b5665248, replyNumber=0, likeNumber=50, createdTime=2015-09-29, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e4b5665248, moduleTitle=吉非替尼联合培美曲塞一线治疗EGFR突变的东亚晚期NSCLC患者优于单纯吉非替尼（JMIT研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e4b5665248)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534277, encodeId=0e6415342e732, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=招募患者：比较MSC2156119J联合吉非替尼与化疗治疗EGFR突变的MET阳性晚期NSCLC患者的Ib及II期临床试验, objectType=article, longId=56022, objectId=21385602249, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21385602249, replyNumber=0, likeNumber=22, createdTime=2015-09-11, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21385602249, moduleTitle=招募患者：比较MSC2156119J联合吉非替尼与化疗治疗EGFR突变的MET阳性晚期NSCLC患者的Ib及II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21385602249)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534276, encodeId=922515342e6ea, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Ann Oncol：厄洛替尼对比化疗一线治疗对EGFR突变NSCLC患者总生存期影响 (OPTIMAL, CTONG-0802研究), objectType=article, longId=54327, objectId=0ab65432efa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ab65432efa, replyNumber=0, likeNumber=33, createdTime=2015-08-03, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ab65432efa, moduleTitle=Ann Oncol：厄洛替尼对比化疗一线治疗对EGFR突变NSCLC患者总生存期影响 (OPTIMAL, CTONG-0802研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ab65432efa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534275, encodeId=696915342e580, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=FDA批准阿斯利康易瑞沙治疗晚期EGFR突变阳性肺癌, objectType=article, longId=53369, objectId=b87053369a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b87053369a1, replyNumber=0, likeNumber=61, createdTime=2015-07-17, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b87053369a1, moduleTitle=FDA批准阿斯利康易瑞沙治疗晚期EGFR突变阳性肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b87053369a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534274, encodeId=e0cb15342e468, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lancet Oncol：阿法替尼治疗晚期非小细胞肺癌的罕见EGFR突变的临床活性, objectType=article, longId=51738, objectId=3c4f51e38bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c4f51e38bb, replyNumber=0, likeNumber=64, createdTime=2015-06-07, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c4f51e38bb, moduleTitle=Lancet Oncol：阿法替尼治疗晚期非小细胞肺癌的罕见EGFR突变的临床活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c4f51e38bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534273, encodeId=d2af15342e3da, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=N Engl J Med.：AZD9291对 EGFR抑制剂抵抗的非小细胞肺癌有效, objectType=article, longId=51444, objectId=091f5144489, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=091f5144489, replyNumber=0, likeNumber=88, createdTime=2015-06-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=091f5144489, moduleTitle=N Engl J Med.：AZD9291对 EGFR抑制剂抵抗的非小细胞肺癌有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=091f5144489)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534272, encodeId=ab1a15342e2eb, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Cancer Discov.：新型Sym004 抗-EGFR抗体混合物用于难治性结直肠癌的临床研究, objectType=article, longId=50762, objectId=f66c50e62c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f66c50e62c2, replyNumber=0, likeNumber=55, createdTime=2015-05-16, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f66c50e62c2, moduleTitle=Cancer Discov.：新型Sym004 抗-EGFR抗体混合物用于难治性结直肠癌的临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f66c50e62c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534271, encodeId=aeac15342e149, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JCO：厄洛替尼治疗EGFR突变肺癌患者有效, objectType=article, longId=50118, objectId=282d5011841, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=282d5011841, replyNumber=0, likeNumber=61, createdTime=2015-05-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=282d5011841, moduleTitle=JCO：厄洛替尼治疗EGFR突变肺癌患者有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=282d5011841)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534270, encodeId=7c8f15342e096, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=NEJM：Rociletinib药物在EGFR突变的非小细胞肺癌效应评估, objectType=article, longId=50094, objectId=e5e1500947f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5e1500947f, replyNumber=0, likeNumber=68, createdTime=2015-05-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5e1500947f, moduleTitle=NEJM：Rociletinib药物在EGFR突变的非小细胞肺癌效应评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5e1500947f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534269, encodeId=2b1a15342690a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=BMC Cancer：FGFR1和FRS2α的表达增加会降低RCC患者的无进展生存期, objectType=article, longId=50059, objectId=70ba50059c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70ba50059c4, replyNumber=0, likeNumber=104, createdTime=2015-05-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70ba50059c4, moduleTitle=BMC Cancer：FGFR1和FRS2α的表达增加会降低RCC患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70ba50059c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534268, encodeId=431a1534268b6, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=招募患者：阿帕替尼治疗晚期EGFR野生型肺癌Ⅲ期临床试验, objectType=article, longId=48418, objectId=7c4d4841853, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c4d4841853, replyNumber=0, likeNumber=86, createdTime=2015-03-21, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c4d4841853, moduleTitle=招募患者：阿帕替尼治疗晚期EGFR野生型肺癌Ⅲ期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c4d4841853)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534267, encodeId=e2d4153426e74, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Gastric Cancer：HER2，EGFR及c-Met状态对晚期胃癌患者总存活的预后影响, objectType=article, longId=47688, objectId=9d5b4e68878, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d5b4e68878, replyNumber=0, likeNumber=70, createdTime=2015-03-05, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d5b4e68878, moduleTitle=Gastric Cancer：HER2，EGFR及c-Met状态对晚期胃癌患者总存活的预后影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d5b4e68878)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534266, encodeId=01a615342667a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lung Cancer：EGFR酪氨酸激酶抑制剂用于EGFR阳性突变的非小细胞肺癌的安全性分析, objectType=article, longId=47552, objectId=24af4e552a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24af4e552a1, replyNumber=0, likeNumber=70, createdTime=2015-03-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24af4e552a1, moduleTitle=Lung Cancer：EGFR酪氨酸激酶抑制剂用于EGFR阳性突变的非小细胞肺癌的安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24af4e552a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534265, encodeId=c492153426525, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Cell:EGFR在自噬发生过程中的激酶非依赖性作用, objectType=article, longId=45748, objectId=3fd945e488c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fd945e488c, replyNumber=0, likeNumber=64, createdTime=2015-01-22, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fd945e488c, moduleTitle=Cell:EGFR在自噬发生过程中的激酶非依赖性作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fd945e488c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534264, encodeId=46e7153426457, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lancet Oncol：阿法替尼未改善EGFR突变阳性肺腺癌患者总生存, objectType=article, longId=45502, objectId=4a86455022f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a86455022f, replyNumber=0, likeNumber=79, createdTime=2015-01-16, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a86455022f, moduleTitle=Lancet Oncol：阿法替尼未改善EGFR突变阳性肺腺癌患者总生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a86455022f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534263, encodeId=d77215342636b, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CCC：一线靶向治疗进展期结直肠癌，抗EGFR优于抗VEGF单抗（ Meta分析）, objectType=article, longId=45297, objectId=edad4529e9b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edad4529e9b, replyNumber=0, likeNumber=77, createdTime=2015-01-11, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edad4529e9b, moduleTitle=CCC：一线靶向治疗进展期结直肠癌，抗EGFR优于抗VEGF单抗（ Meta分析）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edad4529e9b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534262, encodeId=3ccb1534262dc, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Oncologist：阿法替尼治疗EGFR-TKIs获益的非小细胞肺癌患者进展后的经验分析, objectType=article, longId=42035, objectId=067d42035e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=067d42035e9, replyNumber=0, likeNumber=61, createdTime=2014-11-05, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=067d42035e9, moduleTitle=Oncologist：阿法替尼治疗EGFR-TKIs获益的非小细胞肺癌患者进展后的经验分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=067d42035e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534260, encodeId=ae1515342602f, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CSCO 2014：EGFR基因突变状态未知NSCLC治疗——TKIor化疗?, objectType=article, longId=40473, objectId=b6c5404e3cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6c5404e3cc, replyNumber=0, likeNumber=60, createdTime=2014-09-21, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6c5404e3cc, moduleTitle=CSCO 2014：EGFR基因突变状态未知NSCLC治疗——TKIor化疗?, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6c5404e3cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GFR

2020-05-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lung Cancer：吸烟影响EGFR基因突变发生来了和突变模式

2015-11-06

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lancet Oncol：吉非替尼联合铂类化疗用于一线采用吉非替尼治疗的EGFR突变NSCLC进展后治疗并不优于单纯化疗（IMPRESS研究）

2015-09-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

吉非替尼联合培美曲塞一线治疗EGFR突变的东亚晚期NSCLC患者优于单纯吉非替尼（JMIT研究）

2015-09-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

招募患者：比较MSC2156119J联合吉非替尼与化疗治疗EGFR突变的MET阳性晚期NSCLC患者的Ib及II期临床试验

2015-09-11

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Ann Oncol：厄洛替尼对比化疗一线治疗对EGFR突变NSCLC患者总生存期影响 (OPTIMAL, CTONG-0802研究)

2015-08-03

liuyiping (审核中...)

前往app查看评论内容

#GFR#

FDA批准阿斯利康易瑞沙治疗晚期EGFR突变阳性肺癌

2015-07-17

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lancet Oncol：阿法替尼治疗晚期非小细胞肺癌的罕见EGFR突变的临床活性

2015-06-07

liuyiping (审核中...)

前往app查看评论内容

#GFR#

N Engl J Med.：AZD9291对 EGFR抑制剂抵抗的非小细胞肺癌有效

2015-06-01

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Cancer Discov.：新型Sym004 抗-EGFR抗体混合物用于难治性结直肠癌的临床研究

2015-05-16

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JCO：厄洛替尼治疗EGFR突变肺癌患者有效

2015-05-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

NEJM：Rociletinib药物在EGFR突变的非小细胞肺癌效应评估

2015-05-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

BMC Cancer：FGFR1和FRS2α的表达增加会降低RCC患者的无进展生存期

2015-05-01

liuyiping (审核中...)

前往app查看评论内容

#GFR#

招募患者：阿帕替尼治疗晚期EGFR野生型肺癌Ⅲ期临床试验

2015-03-21

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Gastric Cancer：HER2，EGFR及c-Met状态对晚期胃癌患者总存活的预后影响

2015-03-05

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lung Cancer：EGFR酪氨酸激酶抑制剂用于EGFR阳性突变的非小细胞肺癌的安全性分析

2015-03-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Cell:EGFR在自噬发生过程中的激酶非依赖性作用

2015-01-22

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lancet Oncol：阿法替尼未改善EGFR突变阳性肺腺癌患者总生存

2015-01-16

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CCC：一线靶向治疗进展期结直肠癌，抗EGFR优于抗VEGF单抗（ Meta分析）

2015-01-11

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Oncologist：阿法替尼治疗EGFR-TKIs获益的非小细胞肺癌患者进展后的经验分析

2014-11-05

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CSCO 2014：EGFR基因突变状态未知NSCLC治疗——TKIor化疗?

2014-09-21

科室
- - 订阅+
  - 更多科室
工具
服务